FEBRUARY 10, 2026 AT 07:00 AM
AstraZeneca (AZN LN) - Q4 (USD): Core EPS 2.12 (exp. 2.14), Revenue 15.5bln (exp. 15.46bln), guides initial FY26 revenue up by mid-to-high single digit and core EPS up by double-digit percentage
Importance
Level 1
- Q4 Imfinzi revenue USD 1.75bln (exp. 1.61bln).
- FY25 oncology revenue USD 25.62bln (prev. 7.03bln Y/Y)
- Co. gets CDSCO approval for Durvalumab in India.